Literature DB >> 17901260

Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity.

Massimo Stefani1.   

Abstract

Recent knowledge supports the idea that early protein aggregates share basic structural features and are responsible for cytotoxicity underlying neurodegeneration; in most cases, early aggregate cytotoxicity apparently proceeds through similar molecular mechanisms and results in similar biochemical modifications. Data suggest that aggregate cytotoxicity may be considered a generic property of the oligomers preceding fibril appearance. Oligomers can interact with cell membranes, impairing their structural organization and destroying their selective ion permeability, eventually culminating with cell death. This process can be influenced by the physicochemical features and aggregation state of amyloids as well as by the physical and biochemical features of cell surfaces. The roles of synthetic and biological surfaces in affecting protein folding and misfolding, in speeding up aggregate nucleation, and as targets of aggregate toxicity is gaining consideration. Recent research has highlighted the involvement of surfaces as protein-misfolding chaperones and aggregation catalysts and their effects in these phenomena.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17901260     DOI: 10.1177/1073858407303428

Source DB:  PubMed          Journal:  Neuroscientist        ISSN: 1073-8584            Impact factor:   7.519


  21 in total

1.  Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis.

Authors:  Nichole A Reyes; Jill K Fisher; Kathryn Austgen; Scott VandenBerg; Eric J Huang; Scott A Oakes
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

Review 2.  Nucleotide excision repair deficient mouse models and neurological disease.

Authors:  Laura J Niedernhofer
Journal:  DNA Repair (Amst)       Date:  2008-02-12

3.  Aggregation modulators interfere with membrane interactions of β2-microglobulin fibrils.

Authors:  Tania Sheynis; Anat Friediger; Wei-Feng Xue; Andrew L Hellewell; Kevin W Tipping; Eric W Hewitt; Sheena E Radford; Raz Jelinek
Journal:  Biophys J       Date:  2013-08-06       Impact factor: 4.033

4.  Fluctuation methods to study protein aggregation in live cells: concanavalin A oligomers formation.

Authors:  V Vetri; G Ossato; V Militello; M A Digman; M Leone; E Gratton
Journal:  Biophys J       Date:  2011-02-02       Impact factor: 4.033

5.  Role of β-hairpin formation in aggregation: the self-assembly of the amyloid-β(25-35) peptide.

Authors:  Luca Larini; Joan-Emma Shea
Journal:  Biophys J       Date:  2012-08-08       Impact factor: 4.033

6.  Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Ghulam M Ashraf; Nigel H Greig; Taqi A Khan; Iftekhar Hassan; Shams Tabrez; Shazi Shakil; Ishfaq A Sheikh; Syed K Zaidi; Mohammad Akram; Nasimudeen R Jabir; Chelaprom K Firoz; Aabgeena Naeem; Ibrahim M Alhazza; Ghazi A Damanhouri; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

7.  Mistranslation-induced protein misfolding as a dominant constraint on coding-sequence evolution.

Authors:  D Allan Drummond; Claus O Wilke
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

8.  Thermodynamic and structural characterization of an antibody gel.

Authors:  Osigwe Esue; Anna X Xie; Tim J Kamerzell; Thomas W Patapoff
Journal:  MAbs       Date:  2013-02-20       Impact factor: 5.857

Review 9.  Lessons learned from protein aggregation: toward technological and biomedical applications.

Authors:  César L Avila; Silvina Chaves; Sergio B Socias; Esteban Vera-Pingitore; Florencia González-Lizárraga; Cecilia Vera; Diego Ploper; Rosana Chehín
Journal:  Biophys Rev       Date:  2017-09-13

Review 10.  The role of amyloidogenic protein oligomerization in neurodegenerative disease.

Authors:  Gregor P Lotz; Justin Legleiter
Journal:  J Mol Med (Berl)       Date:  2013-03-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.